Get the Stockscreener App
0.1185
5.50%
-0.0069
After Hours:
.12
0.0015
+1.27%
Conduit Pharmaceuticals Inc stock is traded at $0.1185, with a volume of 3.67M.
It is down -5.50% in the last 24 hours and down -3.74% over the past month.
Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being, prioritized by leading biopharmaceutical companies in order to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready in autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.
See More
Previous Close:
$0.1254
Open:
$0.125
24h Volume:
3.67M
Relative Volume:
0.30
Market Cap:
$11.56M
Revenue:
-
Net Income/Loss:
$-4.21M
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-6.18%
1M Performance:
-3.74%
6M Performance:
-96.77%
1Y Performance:
-98.02%
1-Day Range:
$0.115
$0.1265
1-Week Range:
$0.115
$0.132
52-Week Range:
$0.1126
$8.7499
Conduit Pharmaceuticals Inc Stock (CDT) Company Profile
Name
Conduit Pharmaceuticals Inc
Sector
Industry
Phone
(760) 471 8536
Address
4995 MURPHY CANYON ROAD, SUITE 300, SAN DIEGO
Conduit Pharmaceuticals Inc Stock (CDT) Latest News
In the Green: Conduit Pharmaceuticals Inc (CDT) Closes at 0.13, Up/Down -2.64 from Previous Day - The Dwinnex
CDT Stock Sees Decline of Approximately -3.66% in Last Five Days - Knox Daily
Conduit Pharmaceuticals Inc (CDT) expanding its growth trajectory ahead - SETE News
Conduit Pharmaceuticals Inc [CDT] Insider Activity: An Update for Investors - Knox Daily
Metric Analysis: Conduit Pharmaceuticals Inc (CDT)’s Key Ratios in the Limelight - The Dwinnex
Conduit Pharmaceuticals Inc. (NASDAQ:CDT) Director Andrew Regan Sells 1,514,100 Shares - Defense World
Conduit Pharmaceuticals Inc. (NASDAQ:CDT) Director Andrew Regan Sells 150,000 Shares of Stock - Defense World
CDT Shares Experience Decline in Value - Knox Daily
Conduit Pharmaceuticals Inc. (NASDAQ:CDT) Director Andrew Regan Sells 35,923 Shares - Defense World
Mercer Global Advisors Inc. ADV Reduces Stock Position in Dimensional Emerging Markets Core Equity 2 ETF (NYSEARCA:DFEM) - Defense World
Conduit Pharmaceuticals Inc. (NASDAQ:CDT) Director Andrew Regan Sells 1,005,200 Shares - Defense World
Conduit Pharmaceuticals Inc. (NASDAQ:CDT) Director Andrew Regan Sells 1,389,820 Shares - Defense World
Conduit Pharmaceuticals executive sells over $4.5 million in stock By Investing.com - Investing.com Canada
Conduit Pharmaceuticals executive sells over $4.5 million in stock - Investing.com
Conduit Pharmaceuticals executive sells over $4.5 million in stock By Investing.com - Investing.com UK
Are Smart Investors Making the Right Decision? Conduit Pharmaceuticals Inc (CDT) - SETE News
Akoustis Technologies Inc: How Does AKTS Perform? - Stocks Register
CDT’s Stock Market Adventure: -96.92% YTD Growth Amidst Volatility - The InvestChronicle
Was Conduit Pharmaceuticals Inc (CDT)’s session last reading good? - US Post News
Insider’s View: Deciphering Conduit Pharmaceuticals Inc (CDT)’s Financial Health Through Ratios - The Dwinnex
Conduit Pharmaceuticals Inc [CDT] Revenue clocked in at $0.00 million, down -96.87% YTD: What’s Next? - The DBT News
Conduit Pharmaceuticals Inc (CDT) Stock: A Year of Highs and Lows - The InvestChronicle
Stocks of Conduit Pharmaceuticals Inc (CDT) are poised to climb above their peers - SETE News
Is Conduit Pharmaceuticals Inc (CDT) worth investing in despite its undervalued state? - US Post News
Conduit Pharmaceuticals Inc (CDT)’s Ratio Roundup: Key Metrics for Trailing Twelve Months - The Dwinnex
Conduit Pharmaceuticals reschedules annual meeting to December - Investing.com
Conduit Pharmaceuticals reschedules annual meeting to December By Investing.com - Investing.com UK
Healthy Upside Potential: Conduit Pharmaceuticals Inc (CDT) - SETE News
Post-Trade Analysis: Conduit Pharmaceuticals Inc (CDT) Slides -5.38, Closing at 0.12 - The Dwinnex
CDT’s Market Quandary: Decoding the Ups and Downs of 2023 - The InvestChronicle
Why Zhibao Technology Shares Are Trading Higher By Around 19%; Here Are 20 Stocks Moving Premarket - Benzinga
Market news - Research the market
Vela Technologies reports big drop in asset value - ShareCast
Vela Technologies Reports Mixed Quarterly Results - TipRanks
Short Interest in Conduit Pharmaceuticals Inc. (NASDAQ:CDT) Rises By 386.4% - Defense World
CDT’s Stock Dilemma: Conduit Pharmaceuticals Inc’s Market Performance and Outlook - The InvestChronicle
Conduit Pharmaceuticals Inc (CDT) is looking forward to a strong quarter - SETE News
Conduit Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference - StockTitan
Conduit Pharmaceuticals Inc’s Market Journey: Closing Weak at 0.16, Down -1.64 - The Dwinnex
Conduit Pharmaceuticals Inc (CDT)’s stock chart: A technical perspective - US Post News
AI, Biotech Companies at Risk in Nasdaq's Penny Stock Crackdown - Bloomberg Law
Taking on analysts’ expectations and winning: Conduit Pharmaceuticals Inc (CDT) - SETE News
CDT Stock Earnings: Conduit Pharmaceuticals Reported Results for Q2 2024 - MSN
Conduit Pharmaceuticals Inc Inc. (CDT) Price Performance: A Fundamental Analysis Perspective - The InvestChronicle
Ratio Review: Analyzing Conduit Pharmaceuticals Inc (CDT)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Conduit Pharmaceuticals Inc (CDT) is an excellent investment, but the stock is overvalued/undervalued right now - US Post News
Conduit Pharmaceuticals Inc. (NASDAQ:CDTTW) Short Interest Down 11.4% in July - Defense World
CrossFirst Bankshares, Inc. (NASDAQ:CFB) Short Interest Update - Defense World
Conduit Pharmaceuticals faces Nasdaq delisting over market value - Investing.com India
Conduit Pharmaceuticals faces Nasdaq delisting over market value - Investing.com
Conduit Pharmaceuticals faces Nasdaq delisting over market value By Investing.com - Investing.com UK
Conduit Pharmaceuticals Inc Stock (CDT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):